What is Pathios Therapeutics?
Pathios Therapeutics, established in 2017 and based in Oxford, UK, is an early-stage drug discovery firm focused on identifying novel small-molecule modulators of GPR65. The company's scientific approach leverages human genetic insights, transcriptomics, and advanced cellular immunology to map GPCR signaling on immune cells. Pathios has identified GPR65 as a critical innate immune checkpoint on tumor-associated macrophages (TAMs), aiming to develop therapeutic agents for a broad spectrum of cancers and other serious diseases. Their strategy combines an experienced scientific leadership team with strategic external partnerships to accelerate drug discovery.
How much funding has Pathios Therapeutics raised?
Pathios Therapeutics has raised a total of $8.8M across 1 funding round:
Series A
$8.8M
Series A (2019): $8.8M with participation from Medical Research Commercialisation Fund and Canaan
Key Investors in Pathios Therapeutics
Medical Research Commercialisation Fund
The Medical Research Commercialisation Fund, operating under Brandon BioCatalyst, is a leading life science investment fund in Australia and New Zealand, focused on transforming biomedical research into impactful medical products. They specialize in early-stage innovations and partner with research institutes and entrepreneurs.
Canaan
Canaan is an early-stage venture capital firm with a significant track record in backing technology and healthcare companies from seed to growth stages. Their investment focus spans enterprise software, fintech, consumer, biopharma, and digital health.
What's next for Pathios Therapeutics?
The recent major strategic investment signals a pivotal moment for Pathios Therapeutics, likely enabling the company to advance its GPR65-targeting drug discovery program towards clinical development. This capital infusion is expected to fuel further research and development, potentially expanding its pipeline and solidifying its position in the oncology and immunology therapeutic areas. The company's focus on innate immune checkpoints and TAMs aligns with current trends in cancer immunotherapy, suggesting a strategic direction aimed at addressing unmet medical needs.
See full Pathios Therapeutics company page
